Previously featured on:
SynBioBeta's world-class content is matched by the best-in-class digital experience, with even more ways to connect and engage with the people, companies, and ideas that matter most to you.
The pandemic has spurred many new collaborations between synthetic biology and pharma companies. Learn from leading innovators about how synthetic biology has accelerated development in diagnostics, therapies, and vaccines from years to weeks.
With AI-powered networking and interactive features only available through our digital experience, you'll engage and connect with just the right people in synthetic biology, health, academia, the investment community, policy, and more.
Biopharma Day is your one-stop shop for the most cutting-edge synthetic biology platforms. Hear about the latest tools and technologies as they unfold and accelerate product timelines for coronavirus and much, much more.
About Your Host
Hi, my name is John, and I am the founder of SynBioBeta. We help bio-entrepreneurs, companies, investors, researchers, visionaries, and thought leaders who are shaping the future of humanity to connect and bring projects to life.
This year I am proud to bring together the synthetic biology industry and biopharma industry like never before. I can't wait to see you there!
The global synthetic biology conference is here
Synthetic biology approaches are rapidly advancing cancer therapies and transforming how we care for patients. With trials underway to bring living medicines and new immunotherapy solutions online, synthetic biology is poised to transform the landscape of healthcare and medicine. This session will explore the latest innovations and applications, technical challenges, and perspectives from leading innovators.
COVID-19 has challenged our community to deliver new diagnostic platforms, production processes, and therapeutic modalities. What has COVID taught us about going from concept to solution at speed? What are the realities of making these solutions robust and economically viable, often in partnership with others? From drug makers to technology providers, this session brings together diverse perspectives on vaccines, diagnostics, and novel therapeutics in the pandemic response.
Interest in the human microbiome—the ≈2 kilos and trillions of diverse bacteria that inhabit the large intestine—isn’t just hype or a natural healing trend. A significant uptick in basic science is studying the complex relationship between the microbiome, hormones, nervous and immune system, and beyond. While we turn insights into action, will interest in microbiome health fade or accelerate? We’ll look at the latest in microbiome research, explore our complex relationships with natural versus engineered treatments, and how the two might co-exist.
Living medicines, broadly speaking, are modified living biotherapeutics. The term “living” is very important because they’re designed to sense and respond to cues in the human body, then deliver optimal treatment to the specific needs of the patient. They provide treatment at exactly the right dosage, time, and place. It is designed to be smart so it is potentially more powerful and effective than conventional drugs today. In this session, we will hear from the innovators in the field about the latest advances and what's coming next.
Using synthetic biology to design new drugs is still a new thought process, but small and fast-moving innovators already have access to extremely powerful tools in AI, automation, and gene read/write/edit that are changing the pharma landscape. These innovators are not only reducing the time and cost to market, but more importantly bring patients with rare and undertreated diseases hope as small targets become more economically viable. This session profiles four such innovators at the forefront of AI, synbio, and pharma.
Whether it’s testing, treatment, or vaccine development, antibodies are at the center of the research community’s race to put coronavirus behind us. Our distinguished panel in conversation about the latest antibody developments in the fight against COVID-19. We'll discuss breakthroughs, bottlenecks, tech and regulatory hurdles, and the challenges to scale-up.
Cell-free engineering offers an opportunity to decouple the cell’s objectives from our engineering objectives. With new tools and methods for assembling and amplifying genome-scale DNA in vitro, cloning may finally become a thing of the past, not only compressing research times but also expanding what’s possible. This panel will explore the state of the art in cell-free technologies and share some surprising new ways they can be used in therapeutics, cheap diagnostics, and distributed manufacturing.
Meet the featured speakers of the Global Synthetic Biology Conference 2020
Aaron leads Twist Biosciences' biopharma vertical, where he's combining advances in synthesis and antibody engineering. His career has taken him though a number of drug discovery companies, and he knows first-hand many of the bottlenecks in drug development.
Jasmina works with the powerful Ginkgo Foundry platform to see what we can learn from nature and can harness through microbes for use in the personal care and health. Her goal is to fuel a future with new types of ingredients and products, perhaps even some that we can't yet imagine.
A recognized leader in cell-free research, Michael leads Northwestern University's Center for Synthetic Biology. He is a serial company founder looking to the future of pharma and manufacturing, where products are unconstrained by the cell.
Gordon is a biotechnology entrepreneur, and Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is on the board of directors for bio-informatics company Maverix Biomics, as well as Ardelyx, Alexza, and 3V Biopharma.
Co-Founder & CEO
Tim is a pioneer in synthetic biology, and an Associate Professor at MIT. He is a co-founder of Synlogic Tango Therapeutics, Sample6, Eligo, BiomX, and Engine Biosciences. He applies synthetic biology to current immuno-oncology approaches for greater precision and effectiveness.
Co-Founder, Therapeutic Discovery
Leah is a co-founder and the Head of Therapeutic Discovery at 3T Biosciences, and immunotherapy company that discovers novel targets and therapeutics with curative potential for solid tumor patients. She's identifying new immunotherapy targets and T-cell receptors for next-generation cell therapies.
Co-Founder & CEO
Nethaji leads Octarine’s mission to harness synthetic biology to develop functionally superior cannabinoid and psilocybin derivatives for pharma and health. Octarine's in-cell enzymatic platform expands chemical diversity for molecules with improved chemical & pharmacokinetic properties.
Raymond James Financial, Inc.
A chemical engineer by training, Michael’s coverage of the cannabis sector focuses on its pure scientific, engineering, and clinical developments, yielding an evidence-driven, hyperbole-free perspective for the capital markets. Heterologous cannabinoid biosynthesis and synthetic biology are a cornerstone of his research.
Chief Business Officer
Ena is the Chief Business Officer at Ginkgo Bioworks and has more than a decade of experience working in the industry with companies like Amyris, Evolva, Intrexon and Pixar. She oversees new business partnerships and the commercialization of Ginkgo’s technology and products.
Director of Contract Research
Sarah Ives is an immune engineer. She leads the broad-spectrum Centivax flu vaccine program, and 50+ discovery campaigns for biotechnology and pharmaceutical companies across the globe. Sarah and her research are featured prominently in the Netflix docuseries "Pandemic: How to Prevent an Outbreak."
Co-Founder & Chief Research Officer
At Mammoth, Janice is harnessing CRISPR for rapid and affordable disease detection for coronavirus and beyond. A student under CRISPR pioneer Jennifer Doudna, Chen studied how DNA-cutting CRISPR proteins recognize & cut their target, thus enabling more precise gene-editing tools.
Co-Founder, President & CEO
Rachel founded and has lead Caribou since 2011. She is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business.
GET YOUR TICKET TODAY
Come learn the latest technologies, hear the big announcements in the field, make new partnerships, meet investors, and discover new companies that can accelerate your drug discovery & drug manufacturing.
“SynBioBeta is the only synthetic biology conference that pays tribute to strong science and also strong business.”
Roche Venture Fund
“We made several valuable connections, including two potential investors, and a number of future customers.”
Founder, Bento Labs
“A conference not to be missed – this is the place for SynBioBeta power users, experts, key opinion leaders, investors, vendors, students and novices.”
CEO, Twist Bioscience
“SynBioBeta keeps getting better! There is no place that brings together such a crowd of scientists, entrepreneurs, investors, and thought leaders from fortune 500 companies."
Founder & CEO, Arzeda
More content than you can ever imagine
Get a sneak peek of this year's amazing sessions!
ddf The conference will take place on the SynBioBeta platform, available on mobile devices through the App Store and Google Play (search “SynBioBeta”) and through the desktop version.
The conference will take place on the SynBioBeta platform, available on mobile devices through the App Store and Google Play (search “SynBioBeta”) and through the desktop version.
Yes! In fact, networking will be optimized through the use of AI technology. The platform will suggest connections to others based on your own interests in people, sessions, and topics. You can make face-to-face appointments through the platform or connect using the interactive chat.
Explore and connect with our many speakers that are leading the bioeconomy
Copyright 2020 © SynBioBeta. All Rights Reserved.